SAGE

Antiviral Therapy Template

Write in a clean editor, then format for Antiviral Therapy in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the Antiviral Therapy format

Antiviral Therapy is a peer-reviewed journal published by SAGE, covering HIV/AIDS drug development and treatment, HIV Research and Treatment, Hepatitis C virus research.

PublisherSAGE
Reference styleAuthor–year (Harvard)
Author–year — (Smith, 2023) in the text
Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Antiviral Therapy, 12(3), pp. 45–58.

Formats any DOI in Antiviral Therapy style. No sign-up.

Publishes research inHIV/AIDS drug development and treatment HIV Research and Treatment Hepatitis C virus research HIV-related health complications and treatments HIV/AIDS Research and Interventions
ISSN1359-6535
Citation impact (2-yr)1.94
h-index103
i10-index1,687
Total citations71,758
Open accessYes
Top institutions publishing hereInserm
Journal websitewww.intmedpress.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Antiviral Therapy per year

118
2014
99
2015
97
2016
94
2017
86
2018
52
2019
5
2020
19
2021
39
2022
31
2023
11
2024
18
2025

Citation impact of Antiviral Therapy by publication year

2.1K
2014
1.6K
2015
1.5K
2016
1.6K
2017
849
2018
431
2019
67
2020
80
2021
308
2022
241
2023
45
2024
19
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Antiviral Therapy

Silver Nanoparticles Inhibit Hepatitis B virus Replication

Lei Lu, Raymond Wai‐Yin Sun, Rong Chen et al. · 1 Feb 2008

BACKGROUND: Silver nanoparticles have been shown to exhibit promising cytoprotective activities towards HIV-infected T-cells; however, the effects of these nanoparticles towards other kinds of viruses remain largely unexplored. The aim of the present study was to investigate the effects of silver nanoparticles on hepatitis B virus (HBV). METHODS: Monodisperse silver nanoparticles with mean particle diameters…

Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience

J.H. Ko, Hyeri Seok, Sun Young Cho et al. · 1 Oct 2017

BACKGROUND: The effects of convalescent plasma (CP) infusion, one of the treatment options for severe Middle East respiratory syndrome coronavirus (MERS-CoV) infections, have not yet been evaluated. METHODS: Serological responses of CP-infused MERS patients during the 2015 Korean MERS outbreak at a tertiary care centre were evaluated. Serological activity was evaluated with anti-MERS-CoV enzyme-linked immunosorbent…

Human Coronaviruses: What Do They Cause?

Lia van der Hoek · 1 Jan 2007

SARS-CoV, human coronavirus NL63 (HCoV-NL63) and HCoV-HKU1 were first described in 2003, 2004 and 2005 respectively. Nevertheless, discovery of three new human coronaviruses does not necessary represent a sudden increase in emerging infections by new coronaviruses. Only SARS-CoV has recently been introduced to the human population; the other two have been circulating in humans for…

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila et al. · 1 Jan 2000

To assess the relation between resistance to antiretroviral drugs for treatment of HIV-1 infection and virological response to therapy, results from 12 different studies were re-analysed according to a standard data analysis plan. These studies included nine clinical trials and three observational cohorts. The primary end-point in our analyses was virological failure by week 24.…

Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment

Diane Bennett, Mark Myatt, Silvia Bertagnolio et al. · 1 Feb 2008

BACKGROUND: The World Health Organization (WHO) HIV drug resistance (HIVDR) threshold survey method was developed for surveillance of transmitted HIVDR in resource-limited countries. The method is being implemented with minimal resources as a routine public health activity to produce comparable results in multiple countries and areas within countries. Transmitted drug resistant HIV strains will be…

Antiviral Therapy template — frequently asked questions

How do I write a paper in the Antiviral Therapy format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Antiviral Therapy template. When you export, DocuGuru compiles the paper into the official SAGE format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Antiviral Therapy use?
Antiviral Therapy uses Author–year (Harvard) references, shown as author–year markers such as (Smith, 2023) in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Antiviral Therapy, 12(3), pp. 45–58.
Do I need to know LaTeX to submit to Antiviral Therapy?
No. DocuGuru generates the sagej LaTeX class and compiles the PDF for you in the background, so you get a SAGE-ready Antiviral Therapy document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Antiviral Therapy template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Antiviral Therapy format with correct headings, figures, tables, and author–year citations.
Who publishes Antiviral Therapy?
Antiviral Therapy is a multidisciplinary journal published by SAGE. DocuGuru's Antiviral Therapy template matches SAGE's official submission format.
Can I export a submission-ready Antiviral Therapy PDF?
Yes — DocuGuru produces a PDF built with the official Antiviral Therapy template (the sagej class) that is ready to submit to SAGE, together with the matching LaTeX source files.
How much does the Antiviral Therapy template cost?
You can start writing in the Antiviral Therapy template for free. Exporting the final submission-ready Antiviral Therapy PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Antiviral Therapy template